Another recent in vivo study conducted by Liu et al. [62] showed that the administration of ginsenoside Rg5 (20 mg/kg) for 30 days significantly inhibited the PI3K/Akt pathway during BC treatment in a BALB-c nude mice model. The gene discussed is PIK3CG; the disease is breast cancer.